Literature DB >> 18360289

Early changes in T-cell activation predict antiretroviral success in salvage therapy of HIV infection.

Brett D Shepard1, Mona R Loutfy, Janet Raboud, Frank Mandy, Colin M Kovacs, Christina Diong, Michele Bergeron, Victoria Govan, Stacey A Rizza, Jonathan B Angel, Andrew D Badley.   

Abstract

OBJECTIVE: Because effective antiretroviral therapy (ART) reduces immune activation, we hypothesize that early changes in immune activation are associated with subsequent virologic response to therapy.
DESIGN: Observational cohort study.
SETTING: Institutional HIV clinic.
SUBJECTS: Thirty-four adult HIV patients with virologic failure on their current antiretroviral regimen. INTERVENTION: Change to salvage regimen selected by patient's physician. MAIN OUTCOME MEASURES: Measures of immune activation at baseline and at 2, 4, 8, and 24 weeks after enrollment. Data were analyzed by proportional hazards (PH) models.
RESULTS: PH models showed that reductions between baseline and week 2 in expression of CD38 (P = 0.02) or CD95 (P = 0.02) on CD4 T cells were associated with increased likelihood of achieving virologic suppression. Kaplan-Meier analysis demonstrated that patients who had reductions within the first 2 weeks of therapy in CD4 T-cell expression of CD38 (P = 0.003) or CD95 (P = 0.08) were more likely to achieve viral suppression than those who did not.
CONCLUSIONS: Reduced CD4 T-cell expression of CD38 and CD95 occurring within 2 weeks of salvage therapy is associated with subsequent viral suppression. Monitoring CD38 and CD95 may allow earlier assessment of the response to ART.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18360289      PMCID: PMC3149796          DOI: 10.1097/QAI.0b013e31816d9c3b

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  44 in total

1.  Expression of CD28 and CD38 by CD8+ T lymphocytes in HIV-1 infection correlates with markers of disease severity and changes towards normalization under treatment. The Swiss HIV Cohort Study.

Authors:  P Bürgisser; C Hammann; D Kaufmann; M Battegay; O T Rutschmann
Journal:  Clin Exp Immunol       Date:  1999-03       Impact factor: 4.330

2.  Impact of drug resistance mutations on virologic response to salvage therapy. Swiss HIV Cohort Study.

Authors:  P Lorenzi; M Opravil; B Hirschel; J P Chave; H J Furrer; H Sax; T V Perneger; L Perrin; L Kaiser; S Yerly
Journal:  AIDS       Date:  1999-02-04       Impact factor: 4.177

3.  The prognostic significance in HIV infection of immune activation represented by cell surface antigen and plasma activation marker changes.

Authors:  S Plaeger; H Z Bass; P Nishanian; J Thomas; N Aziz; R Detels; J King; W Cumberland; M Kemeny; J L Fahey
Journal:  Clin Immunol       Date:  1999-02       Impact factor: 3.969

Review 4.  Host factors in the pathogenesis of HIV disease.

Authors:  O J Cohen; A Kinter; A S Fauci
Journal:  Immunol Rev       Date:  1997-10       Impact factor: 12.988

5.  Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage.

Authors:  J V Giorgi; L E Hultin; J A McKeating; T D Johnson; B Owens; L P Jacobson; R Shih; J Lewis; D J Wiley; J P Phair; S M Wolinsky; R Detels
Journal:  J Infect Dis       Date:  1999-04       Impact factor: 5.226

Review 6.  HIV-1-specific cytotoxic T lymphocytes and the control of HIV-1 replication.

Authors:  C Jassoy; B D Walker
Journal:  Springer Semin Immunopathol       Date:  1997

7.  Increased numbers of primed activated CD8+CD38+CD45RO+ T cells predict the decline of CD4+ T cells in HIV-1-infected patients.

Authors:  M Bofill; A Mocroft; M Lipman; E Medina; N J Borthwick; C A Sabin; A Timms; M Winter; L Baptista; M A Johnson; C A Lee; A N Phillips; G Janossy
Journal:  AIDS       Date:  1996-07       Impact factor: 4.177

8.  Tumor necrosis factor (TNF) system levels in human immunodeficiency virus-infected patients during highly active antiretroviral therapy: persistent TNF activation is associated with virologic and immunologic treatment failure.

Authors:  P Aukrust; F Müller; E Lien; I Nordoy; N B Liabakk; D Kvale; T Espevik; S S Froland
Journal:  J Infect Dis       Date:  1999-01       Impact factor: 5.226

9.  Human immunodeficiency virus type 1 Nef protein sensitizes CD4(+) T lymphoid cells to apoptosis via functional upregulation of the CD95/CD95 ligand pathway.

Authors:  G Zauli; D Gibellini; P Secchiero; H Dutartre; D Olive; S Capitani; Y Collette
Journal:  Blood       Date:  1999-02-01       Impact factor: 22.113

10.  Induction of Fas ligand expression by HIV involves the interaction of Nef with the T cell receptor zeta chain.

Authors:  X N Xu; B Laffert; G R Screaton; M Kraft; D Wolf; W Kolanus; J Mongkolsapay; A J McMichael; A S Baur
Journal:  J Exp Med       Date:  1999-05-03       Impact factor: 14.307

View more
  2 in total

1.  Antiretroviral therapy in acute and recent HIV infection: a prospective multicenter stratified trial of intentionally interrupted treatment.

Authors:  Paul Volberding; Lisa Demeter; Ronald J Bosch; Evgenia Aga; Carla Pettinelli; Martin Hirsch; Mary Vogler; Ana Martinez; Susan Little; Elizabeth Connick
Journal:  AIDS       Date:  2009-09-24       Impact factor: 4.177

2.  Activation and maturation of peripheral blood T cells in HIV-1-infected and HIV-1-uninfected adults in Burkina Faso: a cross-sectional study.

Authors:  Hans-Georg Kräusslich; Thomas Böhler; Fabrice Tiba; Frans Nauwelaers; Lassana Sangaré; Boubacar Coulibaly
Journal:  J Int AIDS Soc       Date:  2011-12-17       Impact factor: 5.396

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.